1. Johnson SR. lymphangioleiomyomatosis. Eur Respir J. 2006. 27:1056–1065.
2. Oh YM, Mo EK, Jang SH, Yoo CG, Kim YW, Seo JW, et al. Pulmonary lymphangioleiomyomatosis in Korea. Thorax. 1999. 54:618–621.
3. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 2002. 62:5645–5650.
4. Matsumoto Y, Horiba K, Usuki J, Chu SC, Ferrans VJ, Moss J. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol. 1999. 21:327–336.
5. Banner AS. Hormone receptors in lymphangioleiomyomatosis. Chest. 1984. 85:3–4.
6. Matsui K, Takeda K, Yu ZX, Travis WD, Moss J, Ferrans VJ. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med. 2000. 124:267–275.
7. Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med. 1999. 160:628–633.
8. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest. 2004. 126:1867–1874.
9. Taylor JR, Ryu J, Colby TV, Raffin TA. Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med. 1990. 323:1254–1260.
10. Urban T, Lazor R, Lacronique J, Murris M, Labrune S, Valeyre D, et al. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Medicine (Baltimore). 1999. 78:321–337.
11. Johnson SR, Whale CI, Hubbard RB, Lewis SA, Tattersfield AE. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax. 2004. 59:800–803.